sellWeak cluster of 7
Kenneth DiPietro sold $332k of CERE
Chief Human Resources Officer at Cerevel Therapeutics Holdings, Inc.. 8,000 shares at an average of $41.45, traded Dec 22, 2023, filed Dec 27, 2023.
Warning score
35Value
$332k
8,000 shares
Holdings after
24,663
-24% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +15Trade size$332k at market
- +5Share of holdings soldSold 24% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-073306, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 22, 2023 | MOption exercise Common Stock | +8,000 | $3.50 | $28k | 32,663 | Dec 27, 2023 |
| Dec 22, 2023 | SOpen-market sale Common Stock | -8,000 | $41.45 | $332k | 24,663 | Dec 27, 2023 |
| Dec 22, 2023 | MOption exercise Stock Option (Right to Buy)derivative | -8,000 | $0.00 | $0 | 302,242 | Dec 27, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $1.0M 25,000 shares | -49% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.0M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.